Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1343-51. doi: 10.1016/j.ijrobp.2010.07.1986. Epub 2010 Oct 8.

Abstract

Purpose: Concurrent chemoradiation therapy (CCRT) is useful in advanced hepatocellular carcinoma (HCC), but little is known about radiation-induced gastroduodenal complications following therapy. To determine risk factors, we investigated the prevalence and patterns of gastroduodenal complications following CCRT using endoscopy.

Methods and materials: Enrolled in the study were 123 patients treated with CCRT for unresectable HCC between January 1998 and December 2005. Radiation-induced gastroduodenal complications were defined as radiation gastritis/duodenitis, radiation gastric/duodenal ulcer, or other gastroduodenal toxicity associated with radiation, based on Common Terminology Criteria for Adverse Events (CTCAE 3.0). Serious gastroduodenal complications were defined as events occurring within 12 months from completion of CCRT, those requiring prompt therapeutic intervention, or symptoms equivalent to Grade 3 or 4 radiation-related gastroduodenal toxicity, including nausea or vomiting, based on CTCAE 3.0.

Results: A month after completion of CCRT, 65 (52.8%) patients displayed endoscopic evidence of radiation-induced gastroduodenal complications. Radiation gastric and duodenal ulcers were found in 32 (26.0%) and 20 (16.3%) patients, respectively; radiation gastritis and duodenitis were found in 50 (40.7%) and 42 (34.1%) patients, respectively. Radiation-related bleeding was observed in 13 patients (10.6%). Serious gastroduodenal complications occurred in 18 patients (14.6%) and were significantly more frequent in patients with liver cirrhosis than in those without cirrhosis (p=0.043). There were no radiation-related deaths.

Conclusions: Endoscopically detectable radiation-induced gastroduodenal complications were common in HCC following CCRT. Although serious complications were uncommon, the frequency was higher in patients with liver cirrhosis; thus, these patients should be closely monitored when receiving CCRT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antimetabolites, Antineoplastic / administration & dosage
  • Carcinoma, Hepatocellular / therapy*
  • Chemoradiotherapy / adverse effects*
  • Chemoradiotherapy / methods
  • Duodenal Ulcer / diagnosis
  • Duodenal Ulcer / epidemiology
  • Duodenitis / diagnosis
  • Duodenitis / epidemiology
  • Duodenum / radiation effects*
  • Endoscopy, Gastrointestinal*
  • Female
  • Fluorouracil / administration & dosage
  • Gastritis / diagnosis
  • Gastritis / epidemiology
  • Gastrointestinal Hemorrhage / etiology
  • Humans
  • Liver Neoplasms / therapy*
  • Male
  • Middle Aged
  • Nausea / epidemiology
  • Nausea / etiology
  • Prevalence
  • Prospective Studies
  • Radiation Injuries / diagnosis*
  • Radiation Injuries / epidemiology
  • Radiotherapy Dosage
  • Risk Factors
  • Stomach / radiation effects*
  • Stomach Ulcer / diagnosis
  • Stomach Ulcer / epidemiology
  • Vomiting / epidemiology
  • Vomiting / etiology

Substances

  • Antimetabolites, Antineoplastic
  • Fluorouracil